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THE established lines of allogeneic transplantable mouse ascites tumours are
not rejected by their hosts despite theoretical incompatibility. Such tumour
cells are poor in homograft antigens and this has been advanced as an explanation
for their failure to be rejected (Gorer, 1956). They can, nonetheless, be strongly
antigenic. Effective immunity against them can be induced by immunizationl
with X-irradiated (McKee, Garcia, Troeh and Slater, 1959; Revesz, 1960) or
chemically treated (Apffel, Arnason and Peters, 1966) tumour cells and mice
thus immunized will resist an ordinarily lethal dose of virulent tumour. Even in
mice given virulent tumour without prior immunization an abortive host immune
response can frequently be demonstrated (Hartveit, 1962). Invariably, it is
overwhelmed, however, so that spontaneous cure is virtually unknown.
We have found that serial aspiration of their ascitic fluid from tumour-bearing
mice permits an otherwise abortive immune response to become an effective one.
The majority of animals are permanently cured and immune. Attempts to
elucidate the nature of this effect are the subject of the present report.
MATERIALS AND METHODS
Ascites tumours of the following types were studied. Ehrlich's ascites
carcinoma*, EL4 ascites leukaemiat, S-37 ascites sarcoma+, Krebs-2 ascites
tumour§. They were carried by serial passage in adult mice of Swiss, A-jax and
C57B1/6J strains or in a subline originating from C57B1 some years ago and main-
tained since at the Pondville Hospital. EL4 grew only in the Pondville substrain
of C57B1 and in C57B1/6J. The other tumours studied were invariably fatal in
all strains.
At challenge each mouse was given 0 05 ml. of a suspension which contained
two parts ascites to three parts of Locke's solution. The number of tumour cells
contained in this inoculum varied between 2 0 to 2 5 x 106. This challenge dose
was found empirically to give a uniformly lethal but blood free ascites in control
mice.
Paracentesis.-The ascites were evacuated daily using gentle aspiration with
a syringe and 21 gauge needle inserted above the pubis and carried upwards
subcutaneously for 1-5 cm. before entering the peritoneal cavity. This method
was found to avert leakage after withdrawal of the needle. Aspiration was done
*Kindly provided by: *Dr. C. L. Maddock, Children's Cancer Research Fndn., Boston; tDr.
D. B. Amos, Roswell Park Memorial Institute, Buffalo, N.Y.; tDr. R. J. Trapani, Microbiological
Associates; §Dr. A. Hegyeli, Marine Biological Laboratory, Woods Hole, Mass.ACQUIRED IMMUNITY TO MOUSE ASCITES TUMOURS
gently without squeezing. Squeezing was found to promote the appearance of
wall tumours and was quickly abandoned. Initially, aspiration was begun 7 to 10
days after challenge; subsequently, it was found that equally good results could
be obtained ifthe initial paracentesis was deferred till 12 to 14 days after challenge.
Sham paracentesis was done exactly as described above up to the point of aspira-
tion. In one experiment, the fluid removed at paracentesis was made cell-free by
centrifugation then reinjected into the donor mice or into virgin controls. A
second virgin control group was given intraperitoneal saline, the volume of which
was identical to that ofthe ascitic fluid given the first virgin control group. Both
virgin control groups were weighed daily.
Changes in the asciticftuid.-Ascitic fluid volume and cytocrit were determined
and differential cell counts made at multiple intervals after challenge both in mice
subject to daily drainage and in sham treated controls. Proteins were studied
by paper electrophoresis and immunoglobulins were determined in immuno-
electrophoresis using specific antisera to mouse immunoglobulins (Arnason, de
Vaux St. Cyr and Schaffner, 1964).
Testing ofimmunity.--Mice which recovered from their initial tumour challenge
were rechallenged with 2-5 x 106 cells of the same tumour. If they resisted this
challenge they were then challenged with one of the other tumours studied.
Details are given in the tables.
Immunization.-Krebs-2 ascitic fluid was spun three times at 3000 r.p.m., each
centrifugation lasting 10 minutes, and the cell-free supernatant decanted. Groups
ofmice were immunized with 0 01, 0-05, 0-25 or 1-25 ml. ofthe cell-free ascitic fluid
intraperitoneally and challenged with 2-5 x 106 virulent Krebs-2 tumour cells
intraperitoneally 7 days later.
RESULTS
Daily tapping cured the majority of animals. Table I documents our overall
TABLE I.-Results ofSerial Tapping in Three Lethal Ascites Tumours of Mice
Outcome
Tumour type Treatment Died Recovered Solid growth
Ehrlich ascites . None . 96 0 0
Sham treated . 40 0 0
Tapped . . 57 204 17
EL-4 . . None . . 79 0 0
Sham treated . 20 0 0
Tapped . . 49 146 10
S-37. . . None . . 40 0 0
Tapped . . 6 28 6
experience to date. No spontaneous recurrence of any of the tumours studied
has been seen in cured animals; all have been kept for at least 6 months beyond
the end of experimentation.
Cellular events.-An influx of host cells into the ascites began on the 11th day
after inoculation in EL4 tumour bearing mice and on the 13th day afterinoculation
in those bearing Ehrlich ascites and S-37 tumours. The incoming host cells were
approximately equally divided between polymorphonuclears and mononuclears.
Up to this time 85% or more of the cells in the ascitic fluid were tumour cells but
-with the influx of host cells this proportion fell rapidly. With EL4 tumours the
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host cell response was maximal on day 14, with Ehrlich ascites tumours on day 16
when up to 9000 of the cells were of host origin in mice previously subjected to
one or more paracentesis, and up to 400o were host cells in mice never previouslv
tapped or in which the ascitic fluid removed at tapping was freed of its tumour
cells and reinjected (vide infra). The time of onset of these events was not influ-
enced by prior tapping. Mice tapped daily from the 7th day onward showed the
same tempo of events as those not tapped till day 14. Coincident with this host
response the cytocrit in the ascites fell precipitously from a level ofbetween 24 and
4000 to a level of from 7 to 150. Although fluid tended to collect for a few more
days it was clearer than before. On some occasions rosettes of small round cells
ofthe type described first by Kidd and Toolan (1950) were seen to surround tumour
cells. When 5 x 106 cells, obtained by peritoneal lavage immediately after
recovery from Ehrlich ascites tumour, were given to virgin control mice and these
mice were challenged 3 days later with Ehrlich ascites tumour the inoculum failed
to take.
Immunoelectrophoresis of pooled ascitic fluids taken 7, 13 and 17 days after
challenge with Ehrlich ascites tumour showed low levels of all 3 mouse immuno-
globulins studied (IgG, IgM and IgA) at 7 and 13 days and a massive increase of
IgA at 17 days. The nomenclature of mouse immunoglobulins is discussed in
Arnason, de Vaux St. Cyr and Schaffner (1964).
The ascites were removed from one group ofmice on the 8th day following which
the peritoneal cavity was washed out with saline so as to get an idea ofthe number
of residual tumour cells. 3 x 107 tumour cells per mouse were found.
Effect of replacing cell-free asciticfluid.-When this was done, the animals died
more quickly than inoculated mice which were not tapped at all. Injection of the
cell-free ascitic fluid failed to produce any evident toxic effect in normal mice.
Their weight did not vary from that of a control group given a like volume of
saline. The results are shown in Table II.
TABLE II.-Role of (1ell-Free Ehrlich Ascites Fluid in Host-Defence
Tireatment IMortality
Paracentesis . 9/40
Paracentesis with re-injection of cell-fiee fluidl 20/20*
None 20/20
* Death occuiied eailier than in untreated groul).
Resulting imnbunity. Results are compiled in Table III. Immunity againist
the original tumour was complete. There was also a surprising degree of cross-
immunity.
mnmnmunity achieved by active imnmunization with cell-free ascitic supernat(nt.-
The results with Krebs-2 ascites are given in Table IN'. Seventy-nine per cent of
TABLE IlI.-Imnmunity and C8ross-Imnmunity of Recovered Animnals
Oriigiinal Challenge Numhbe of Number Wall Per cent
tuImiouIr tumour challenges challenge(d Ascites tumours Resistaint resistant
Elirlich asc. ca. .Ehrlieh ase. ca. 3 179 2 16 . 161 . 90
Ehrlich asc. ca. .ETL4 ascites 1 37 2 0 35 94
Ehrlich ase. ca. .Kiebs-2 1 44 0 0 44 (0(
Elhrlich ase. ea. .C1498 I 25 . 17 0 8 32
EL4 aseites .EL4 ascites 3 76 5 6 65 S5
ET4 ascites .C1498 I 23 19 0 4 17
Krebs-2v Krebs-2 1 64 . 3 . 1 . 60 . 94ACQUIRED IMMUNITY TO MOUSE ASCITES TUMOURS
TABLE IV.-Immunization Against Krebs-2 Ascites with Cell-Free
Ascitic Fluid
Number of mice developing
AVolume in iml. of ascitic fluid ascites on challenge at 7
used to immunize days
0*00 19/20 (95)*
0*01 . 4/19 (21)
0*05 12/30 (40)
0 25 . 20/29 (69)
1-2 . 17/20 (85)
* ( ) Percentage developing ascites.
mice given 0.01 ml. of supernatant were immune 7 days later to a challenge which
killed 9500 of control virgin mice. The percentage of animals immunized fell
progressively as the immunizing dose was increased to 0 05, 025 or 1-25 ml. The
table represents the pooled results of 3 individual experiments all of which gave
closely comparable results. When volumes of less than 0 01 ml. of ascitic fluid
have been used for immunization no immunity has been observed. We have
succeeded also in immunizing a considerable proportion of mice to Ehrlich ascites
tumour using a cell-free supernatant of ascitic fluid.
DISCUSSION
The only report we have found in which paracentesis of ascites has been
reported to cure animals bearing compatible allogeneic tumours is that ofTinyakov
and Bulochnikova (1963). These workers noted that " if the exudate of Ehrlich
ascites is aspirated with a syringe, the anti-tumour defensive mechanisms of the
body exert their influence and actual full recovery may ensue." No experimental
details were given.
Tapping removes both tumour cells and the fluid which surrounds them.
AMany tumour cells are left behind, however, and these are sufficient to kill the
animal when the supernatant is replaced. In the absence ofthe supernatant, then,
the host response is effective; in its presence the response is ineffectual. XVe
have demonstrated that the time at which the host immune response first becomes
evident is identical whether the ascitic fluid is left to accumulate throughout the
induction period or whether it is kept to a minimum by daily tapping. The
presence of the ascites seems, therefore, not to interfere with the induction of the
immune response in any way. Instead, its action must be upon the later or
effector side of the host response. The possibility that the ascites exerts a cyto-
toxic effect on the immune effector cells, while unlikely, is difficult to exclude. If
such a cytotoxic effect does exist it must be relatively selective since no generalized
toxic effect of ascitic fluid on normal mice could be demonstrated.
A more likely function of the ascites can be postulated and this would be to
neutralize the antibodies and sensitized cells of the host before they can reach the
tumour cells. The ascites would be acting, then, as a large pool ofreadily accessible
antigen. Direct evidence that mouse tumour ascites does in fact contain large
amounts of histocompatibility antigen is afforded by the experiments of Davies
(1962) who used ascitic fluid as his starting material for the preparation of histo-
compatibility antigen. Further evidence for the antigenicity of ascitic fluid is
provided by the experiments reported here, wherein cell-free ascitic fluid was
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found to be an effective antigen for the induction of tumour immunity. Interest-
ingly, larger amounts of ascitic fluid were less effective in producing tumour
immunity than lesser amounts. Perhaps the larger doses favoured the production
of tolerance rather than of an immune response, though it should be borne in
mind that an immune response did occur regularly in mice bearing large volumes
of ascites at the time the response began. Alternatively, enough residual ascitic
fluid antigen might still have been present when the mice were challenged with
virulent tumour cells at 7 days, to absorb out the greater part of the immune
response.
Whether the immunity achieved depends upon a response to histocompatibility
antigens or upon a response to " tumour antigens " must remain for the moment
an open question. At first consideration the extensive cross-immunity achieved
might be taken as evidence favouring a response to histocompatibility antigens
shared by the tumours since " tumour specific antigens " have been found in
general not to cross react. It should be remembered, nevertheless, that all of the
tumours studied share the property of provoking an ascites and of shedding their
histocompatibility antigens into the ascitic fluid. They behave then as a class and
a " class specific " tumour antigen, specific to the so-called " universal " tumours,
could quite reasonably be postulated.
SUMMARY
When mice bearing transplantable ascitic tumours were treated by daily
withdrawal of ascitic fluid they recovered completely. Recovered animals were
immune to the original tumour on subsequent challenge. They also had extensive
cross-immunity to other ascitic tumours. Evidence is presented that cell-free
ascitic fluid is rich in tumour antigen and that its removal by tapping, rather than
removal of the tumour cells themselves, is the crucial factor in the immunity
achieved.
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